Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of GH is 139 and suggests 64% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell